Ask AI
ProCE Banner Activity

EMBER-3 Patient-Reported Outcomes: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After PD on Previous ET

Conference Coverage
Slideset

In the phase III EMBER-3 trial, patient-reported global health score/QoL and functional domains remained stable with imlunestrant with or without abemaciclib and vs SoC ET in patients with ER+/HER2- advanced breast cancer following progression on previous endocrine therapy.

Released: June 02, 2025

Expiration: December 01, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.